The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance.

N6-methyladenosine (m⁶A) RNA methylation has been considered the most prevalent, abundant, and conserved internal transcriptional modification throughout the eukaryotic mRNAs. Typically, m⁶A RNA methylation is catalyzed by the RNA methyltransferases (writers), is removed by its demethylases (erasers), and interacts with m⁶A-binding proteins (readers). Accumulating evidence shows that abnormal changes in the m⁶A levels of these regulators are increasingly associated with human tumorigenesis and drug resistance. However, the molecular mechanisms underlying m⁶A RNA methylation in tumor occurrence and development have not been comprehensively clarified. We reviewed the recent findings on biological regulation of m⁶A RNA methylation and summarized its potential therapeutic strategies in various human cancers. [ABSTRACT FROM AUTHOR]